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BACKGROUND. Prostate cancer (PCa) frequently metastasizes to the bone and induces
osteoblastic lesions. We previously demonstrated through over-expression of the Wnt inhibitor
dickkopf-1 (DKK-1) that Wnts contribute to the osteoblastic component of PCa osseous lesions
in vivo.
METHODS. To test the clinical significance of DKK-1 expression during PCa progression,
tissue microarrays were stained for DKK-1 protein by immunohistochemistry.
RESULTS. DKK-1 expression index (EI) was found to increase in PIN and primary lesions
compared to non-neoplastic tissue (106 10 vs. 19 6, respectively, where the EI is the product
of the percent expression and staining intensity). DKK-1 expression was also found to be higher
in all PCa metastatic lesions (56 21 EI) compared to non-neoplastic tissues but was
significantly decreased versus primary PCa lesions (P< 0.008). The decline in DKK-1 correlated
with a shift of b-catenin staining from the nucleus to the cytoplasm suggesting possible
mechanism for the observed decrease in DKK-1 levels during PCa progression. Within
metastatic lesions, DKK-1 expression was least abundant in PCa bone metastases relative to all
soft tissue PCa metastatic lesions except lymph node metastases. High DKK-1 expression within
PCa metastases was further associated with shorter over-all patient survival.
CONCLUSIONS. Taken together, these data demonstrate that elevated DKK-1 expression is
an early event in PCa and that as PCa progresses DKK-1 expression declines, particularly in
advanced bone metastases. The decline of DKK-1 in bone metastases can unmask Wnts’
osteoblastic activity. These data support a model in which DKK-1 is a molecular switch that
transitions the phenotype of PCa osseous lesions from osteolytic to osteoblastic. Prostate 68:
1396–1404, 2008. # 2008 Wiley-Liss, Inc.
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INTRODUCTION
Prostate cancer (PCa) remains a significant health
problem in men within the United States. Metastases
of the axial skeleton are a frequent complication and
occur in over 80% of all men who die of PCa [1]. PCa
bone metastases are characterized by regions of new
bone formation (osteogenesis) with underlying areas
of bone resorption (osteolysis). A number of factors
have been implicated in PCa osteogenesis in vitro [2]
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and in vivo including bone morphogenetic protein-6 [3]
and Wnt [4].
The Wnt proteins are a large family of soluble
glycoproteins that are essential for normal bone
development (reviewed in Refs. [5,6]). The activity of
Wnt proteins is controlled by secreted antagonists
including secreted FZD-related proteins (sFRP), Wnt
inhibitory factor-1 (WIF-1), Cerberus, Sclerostin, and
Dickkopfs (DKK) [7]. The spatial and temporal expres-
sion of Wnt inhibitors is critically important for proper
skeletalgenesis. Deletion of a single allele of DKK-1
leads to increased bone mass [8] where as DKK-1 null
mice develop fusion and duplication of digits [9].
Conversely, the osteoblast specific expression of DKK-1
in the mouse led to severe osteopenia further support-
ing that disruption of canonical Wnt signaling results in
significant limb defects in the developing embryo [10].
Proper Wnt signaling is also necessary for main-
tenance of bone mass in adult animals. Specifically,
mice deficient in sFRP1 were shown to have increased
trabecular bone accrual without defects in cortical bone
[11]. This demonstration that changes in Wnt antago-
nists can affect adult bone suggests a mechanism that
can be co-opted by tumor cells to influence bone
remodeling. Tian et al. [12] observed that DKK-1 was
detected in the bone marrow plasma of patients with
multiple myeloma (MM). Elevated DKK1 levels were
associated with the presence of focal bone lesions
suggesting that DKK-1 participated in the development
of osteolytic disease [12]. Subsequently, DKK-1 expres-
sion was found to be evaluated in patient specimens of
MM, breast cancer, and Barrett’s metaplasia suggesting
that DKK1 is a potential prognostic and diagnostic
marker in these diseases [13–16].
We have shown that reducing Wnt activity in PCa by
increasing DKK-1 expression affects the phenotype of
bone metastases in a murine model [4]. Specifically,
the enforced expression of DKK-1 into C4-2B PCa
cells (a PCa cell line that produces mixed osteoblastic
and osteolytic lesions in bone) transformed these cells
into a highly osteolytic tumor in vivo. As PCa bone
metastases contain areas of both osteolytic and osteo-
blastic activity, these data suggest that modulation of
DKK-1 expression could play a role in the development
of PCa bone metastasis. Accordingly, we preformed a
retrospective analysis of DKK-1 protein expression
in human PCa tissue samples to determine whether
DKK-1 was expressed or altered during PCa progres-
sion. We report that DKK-1 protein is found early in
PCa development and decreases in advanced bone
metastases supporting a role for Wnts in PCa-induced
osteogenesis. In addition, elevated DKK-1 protein
levels within PCa metastases were found to be asso-
ciated with shorter overall patient survival. These
data support a model in which DKK-1 is a potential
therapeutic target and a molecular switch between
osteolytic and osteoblastic disease.
MATERIALSANDMETHODS
Case Selection and Tissue Microarrays
A PCa progression tissue microarray (TMA) was
constructed from cases of clinically localized PCa
obtained from a radical prostatectomy series at the
University of Michigan. PCa metastases TMAs were
developed from samples obtained through the Rapid
Autopsy Program within the Michigan Prostate
SPORE Tissue Core [17]. The progression TMA
100 consisted of 309 evaluable cores taken from 99 total
patients; 92 cores of non-neoplastic prostate (from
39 cases), 23 cores of BPH (from 8 cases), 19 cores of PIN
(from 12 cases), 142 cores of localized PCa (from 50
cases), and 33 cores of metastatic, hormone-refractory
PCa (from 11 cases) [18]. Two PCa autopsy arrays 79A
and 79B were constructed from soft tissue and bone
metastases taken from 30 available autopsies. TMA 79A
consists of 303 evaluable cores of primary PCa and
soft tissue metastases of the liver, lung, lymph node,
adrenal, bladder, dura, and seminal vesicles. The TMA
79B consisted of 129 evaluable cores included 72 cores
(from 17 cases) of bone metastases in addition to
primary PCa and soft tissue metastases. All tissue
procurement and analysis in this study was approved
by the Institutional Review Board. Histological proc-
essing of all clinical samples was performed in the
University of Michigan Hospital’s accredited Patho-
logy Department using a standardized procedure to
assure uniform sample preparation for each TMA.
Immunohistochemistry and Evaluation
TMA slides were deparaffinized, rehydrated to
water, and antigen retrieved by pretreatment with
Citrate Buffer, pH 6.0 for 10 min with microwaving.
After peroxidase blocking, the slide were incubated
with 1:400 dilution of goat anti DKK-1 pAb (ab22827,
Abcam Inc., Cambridge, MA) on a DAKO AutoStainer
using the LSABþ detection kit and counterstain with
hematoxylin. Staining intensity was scored by a
genitor-urinary pathologist as negative [1], weak [2],
moderate [3], or strong [4] based on the amount of stain
detected as previously described [19]. The percent of
positive stained cells was determined by counting
100 cells in 2 random fields. DKK-1 protein levels in
each sample were measured based on its expression
index (EI), which is a product of DKK-1 staining
intensity and the percentage of positive staining as
described previously [20]. Identical TMAs were also
stained for b-catenin expression using a mouse anti
b-catenin mAb (clone 14, BD-Transduction, San Diego,
CA) as above.
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To confirm the specificity of both the DKK-1 and b-
catenin antibodies, control IHC studies were pre-
formed. Serial sections from paraffin embedded tumor
tissue produced by DKK-1þ/b-catenin PC-3 shRNA
control transfected PCa cells or DKK-1/b-cateninþ
PC-3 DKK-1shRNA transfected PCa cells were stained
for DKK-1 and b-catenin using the above described
methodology. Primary antibody was also excluded on
identical sections to evaluate non-specific binding
of secondary antibody.
Statistical Analysis
A box plot was used to chart DKK-1 expression in the
progression array. The EI, which is the product of the
staining intensity and percent expression, was ana-
lyzed to determine differences in expression between
the primary tumor and metastases samples using a
linear regression mixed model to account for the
correlation of the samples within each patient. Prod-
uct-limit methods were used to determine the median
survival times in patients with low and high expres-
sions of DKK-1. The Kaplan–Meier estimates were
plotted for each group and the log-rank P-value was
reported. SAS 9.1 (SAS Institute, Cary, NC) was used to





To conduct a retrospective analysis of DKK-1 protein
expression in human PCa patient specimens, tissue
microarrays (TMA) were prepared by the University of
Michigan PCa SPORE tissue core. Two types of TMAs
were evaluated: A progression TMA that contained a
selection of non-neoplastic prostate, BPH, PIN lesions,
primary lesions, and metastases and two autopsy
arrays that were composed of soft tissue and skeletal
metastases. The advantage of a TMA for biomarker
analysis is that the TMA provides a platform for the
simultaneous evaluation of multiple patients, tumor
grades and stages on a single slide thus reducing the
variability inherent in multiple single sample analyses.
This coupled with uniform sample preparation gives
one a high degree of confidence that differences in
DKK-1 staining are reflective of the disease stage. These
TMAs were used to evaluate DKK-1 protein levels
during progression and to explore the impact of organ
site on DKK-1 protein expression.
To confirm the specificity of the DKK-1 antibody,
serial sections from paraffin embedded tumor tissue
produced by DKK-1þ PC-3 shRNA control transfected
PCa cells or DKK-1 PC-3 DKK-1shRNA transfected
PCa cells were stained for DKK-1 protein. Primary
antibody was also excluded on identical sections to
evaluate non-specific binding of secondary antibody.
In these control studies, secondary antibody alone did
not stain the human PCa tumor tissue (Fig. 1A, top
row). DKK-1 was detected in only those tumors formed
by PC-3 shRNA control transfected cells (Fig. 1A,
bottom row) thus confirming the antibody selectively
detected human DKK-1 protein.
The progression TMA contained a total of 309
evaluable cores representing 99 total PCa patients.
The Prostate
Fig. 1. DKK-1decreases in PCa clinical sampleswithprogression.
A: Specificity of DKK-1 antibody. Serial sections from paraffin
embedded tumor tissueproducedbyDKK-1þPC-3 shRNAcontrol
transfected PCa cells or DKK-1 PC-3 DKK-1shRNA transfected
PCa cells were incubatedusing the protocol described inMaterials
and Methods Section with secondary only or primary antibody to
DKK-1.B: AprogressionTMAthatcontains a selectionofnon-neo-
plastic prostate, BPH,PIN, primary tumors (mostly Gleason score
7^ 8)andsofttissuemetastaseswasstainedforDKK-1usingroutine
immunohistochemistry. Shown are tissue cores that represent
the median of DKK-1 expression index of normal prostate, PIN,
primary PCa and PCa metastases presented in Figure 2A (200).
Browncolor indicatesDKK-1staining. [Color figurecanbeviewedin
theonlineissue,whichis availableatwww.interscience.wiley.com.]
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The metastases on the progression array consisted of
PCa lymph node and liver metastases only. Analysis
of DKK-1 staining demonstrated that the protein was
restricted to epithelial cells in all samples (Fig. 1B).
Qualitative evaluation of DKK-1 staining showed that
DKK-1 was found at low levels in normal prostate
tissue but increased significantly in both PIN and
primary PCa lesions (Fig. 1B). In PCa metastases, DKK-
1 staining appeared greater than normal prostate but at
significantly lower levels compared to primary PCa
tumors (Fig. 1B). Total changes in DKK-1 protein
staining were evaluated as previously described using
an EI, which is the product of the staining intensity and
percent expression [20]. DKK-1 EI increased 500% in
primary lesions compared to normal prostate and
BPH (Fig. 2A). However, DKK-1 EI decreased 47%
in metastatic lesions compared to primary tumors
(mean SEM, median; normal prostate: 19.3 5.6, 0;
BPH: 5.2 3.8, 0; primary PCa: 106.0 10.4, 60; PCa
metastases: 56.3 21.5, 0; P< 0.008 PCa metastases vs.
primary lesions). Taken together, the data demonstrate
that DKK-1 protein expression increased during PCa
development but decreased as the tumor progressed.
DKK-1Protein Is Expressedat Low LevelsWithin
Bone Metastases Compared to
Soft Tissue Metastases
To evaluate the impact of organ site on DKK-1
protein expression, autopsy arrays composed of soft
tissue and skeletal metastases were evaluated. The
autopsy TMAs were comprised of nine types of
metastatic lesions from 30 total PCa patients. We have
shown that DKK-1 protein was higher in PCa primary
lesions compared to the pooled PCa metastases of the
lymph node and liver (Fig. 2B). Evaluated individually,
DKK-1 protein in PCa primary lesions was greater than
each of PCa metastases of the lung, liver, bone, adrenal,
and lymph node (Fig. 2B) (mean SEM, median;
primary PCa: 105.9 15.6, 60; lung: 99.5 17.9, 20;
liver: 83.9 15.4, 0; bone: 66.7 13.4, 0; adrenal:
62.5 49.2, 0; lymph node, 53.8 12.7, 0). DKK-1 was
also found to be increased over PCa primary lesions in a
number of soft tissue metastases including the bladder,
dura, and seminal vesicles (Fig. 2B) (mean SEM,
median; dura: 154.3 36.2, 170; bladder: 201.7 37.5,
180; seminal vesicles: 200 70.7, 250). These data
confirm that DKK-1 protein expression is reduced in
PCa skeletal metastases compared to PCa primary
lesions.
Nuclearb-Catenin and DKK-1Concomitantly
Decrease During PCa Progression
Aberrant b-catenin signal transduction has been
implicated in the development of several types of
cancer including PCa [21]. We therefore evaluated
b-catenin protein expression within prostate epithelial
cells on the progression TMA and related these data to
DKK-1 protein expression. In addition to determining
the staining intensity and percent expression, the
distribution of b-catenin (membranous, cytoplasmic,
or nuclear) was also recorded. As with the DKK-1
antibody, the specificity of the b-catenin antibody was
The Prostate
Fig. 2. DKK-1proteinisexpressedatlowlevelswithinbonemeta-
stases compared to soft tissue metastases.A: Box plot of DKK-1
expression index (EI) by tumor stage from the progressionTMA
where the EI is the product of the staining intensity and percent
expression for each core.Graph key: box marks the 25 ^75th per-
centiles; whiskers are the maximum and minimum observation
betweenthe25thand75thinter-quartilerange; theX’smarkvalues
outside the IQR; the bar is the data median and the plus the data
mean. *P< 0.008versusprimaryPCa.B:BoxplotofDKK-1expres-
sion index (EI) within PCa skeletal and soft tissuemetastases from
theautopsyTMAs.
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confirmed by control IHC studies of tumor tissue
produced by b-catenin PC-3 shRNA control trans-
fected PCa cells or b-cateninþ PC-3 DKK-1shRNA
transfected PCa cells. Primary antibody was also
excluded on identical sections to evaluate non-specific
binding of secondary antibody. In these control
studies, secondary antibody alone did not stain the
human PCa tumor tissue (Fig. 3A, top row). b-catenin
was detected in only those tumors formed by PC-3
DKK-1shRNA transfected cells (Fig. 3A, bottom row)
thus confirming the antibody selectively detected
human b-catenin protein.
Qualitative evaluation of b-catenin staining on the
progression TMA showed that the staining intensity
was strong and percent expression approached 100% in
the epithelial cells of normal, BPH, PIN, and primary
PCa lesions (Fig. 3B). However, in epithelial cells of
PCa metastases both the total and nuclear staining of
b-catenin protein appeared to decrease (Fig. 3B,C).
Quantitative analysis of b-catenin protein percent
The Prostate
Fig. 3. Totalb-cateninandDKK-1concomitantlydecreaseduringPCaprogression.A: Specificityofb-cateninantibody. Serial sections from
paraffin embedded tumor tissueproducedbyb-catenin PC-3 shRNAcontrol transfectedPCacells orb-cateninþ PC-3DKK-1shRNAtrans-
fected PCa cells were incubatedusing the protocol described inMaterials andMethods Sectionwith secondary only or primary antibody to
b-catenin.B: A progressionTMAwas stained for b-catenin using routine immunohistochemistry. Shown are tissue cores that represent the
medianofb-cateninpercentexpressionofnormalprostate,PIN,primaryPCaandPCametastasespresentedinFigure4A(200).Browncolor
indicates b-catenin staining.C: High power (400) magnification of primary PCa andmetastatic lesions showing reduced nuclear b-catenin
staining. [Color figurecanbeviewedin theonlineissue,whichis availableatwww.interscience.wiley.com.]
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expression confirmed b-catenin staining in 100% of
normal, PIN, and primary PCa samples (Fig. 4A).
Further, the distribution in these samples was 80%
membranous with 20% nuclear staining (Fig. 4B).
However in epithelial cells of PCa metastases, total
b-catenin protein decreased to 64.5% and was distrib-
uted between the membrane and the cytoplasm, 66.3%
versus 33.7%, respectively (Fig. 4B). DKK-1 was
recently described as a gene target of b-catenin [22].
The fact that nuclear b-catenin was high in epithelial
cells of PCa primary lesions but declines in epithelial
cells of PCa metastases is consistent with the observa-
tion that b-catenin regulates DKK-1.
High DKK-1Levels Are Associated With
Shorter Overall Survival
To determine whether DKK-1 protein expression
correlated with patient survival, the time interval from
diagnosis to death was plotted against DKK-1 protein
in the metastases from the autopsy arrays. The
prognostic value of DKK-1 expression could not be
evaluated in primary tumors because of insufficient
follow-up on patients who appear on the progression
TMA. However, the autopsy arrays contained suitable
temporal data to correlated DKK-1 protein expression
in metastatic lesions with patient survival. For this
analysis, the metastatic lesion with the highest DKK-1
levels was determined for each patient. The median of
the maxscores (200 EI) was then used separate patients
into two groups. DKK-1 EI values greater than 200 were
considered high expression whereas DKK-1 EI values
less than 200 were considered low expression. Of
the 30 patients represented in the autopsy array,
survival data was available for 23 patients. Median
overall survival in high DKK-1 expression group
was 60 months which was less than the low DKK-1
expression group at 90.5 months, P< 0.07, indicating
that DKK-1 protein expression inversely correlated
with patient survival (Fig. 5). To our knowledge this
is the first report to show that high levels of a Wnt
inhibitor are associated with poor patient survival.
DISCUSSION
In the present study, we demonstrated that DKK-1
protein increases during PCa development but
decreases in skeletal metastases compared to primary
tumors. We further provide evidence that elevated
levels of DKK-1 protein in PCa metastases were
associated with shorter patient survival. These results
The Prostate
Fig. 4. Nuclear b-catenin decreases in PCa metastases. The
expression of b-catenin was evaluated on a progression TMA by
immunohistochemistry. The percent of positive stained cells was
determinedby counting100 cells in 2 random fields.A: Box plot of
b-cateninproteinstainingversustumorstage.Graphkey:boxmarks
the 25 ^75thpercentiles;whiskers are themaximumandminimum
observationbetweenthe25thand75thinter-quartilerange; theX’s
markvalues outside the IQR; thebar is thedatamedianandtheplus
thedatamean.*P< 0.005versusprimaryPCa.B:Graphofb-catenin
percent expression in three cellular locations: membrane, cyto-
plasm,andnucleus.
Fig. 5. ElevatedDKK-1proteinlevels areassociatedwith shorter
overall survival. Kaplan^Meier plot of patient survival. The meta-
static lesion with the greatest DKK-1 expression index (EI) was
determined for each patient.Themedian of the DKK-1maxscores
(200 EI) was used as a cutoff to separate patients into two groups;
high DKK-1 expression (values greater than 200) or low DKK-1
expression (values less than or equal to 200).DKK-1EI was plotted
againstpatient survival fromdiagnosis todeath,n¼ 23,P< 0.07.
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support a model in which DKK-1 is a potential
therapeutic target and a molecular switch between
osteolytic and osteoblastic disease.
We previously reported that osteolytic PCa cells
express abundant DKK-1 protein where osteoblastic
PCa cells do not [4]. Blocking DKK-1 expression in
osteolytic PCa cells stimulated osteoblast differentia-
tion and mineralization in vitro [4]. Conversely, DKK-1
over-expression in osteoblastic PCa cells suppressed
bone formation and induced osteolytic lesions in vivo
[4]. We concluded that Wnts mediate PCa osteoblastic
response and that DKK-1 expression should decrease
in clinical PCa bone metastases to allow Wnt-mediated
bone formation. The clinical observations are in agree-
ment with our experimental data in that DKK-1 protein
is decreased in PCa skeletal metastases compared to
PCa primary lesions and other soft tissue metastases.
During the preparation of this manuscript, Li et al. [23]
published an analysis of DKK-1 expression in six
samples of non-neoplastic prostate, nine samples of
primary PCa, and 38 bone metastasis samples. They
report DKK-1 was negative in normal PCa, primary
PCa, and 74% of osteoblastic bone metastases but was
detected in two of three osteolytic bone lesions. The
discrepancy between this and our data is likely because
the published study was not sufficiently powered.
However, these data are in agreement that DKK-1
protein is found at low levels in the majority of PCa
bone metastases thus supporting a role of Wnts in PCa
osteoblastic activity.
A role of Wnt signaling in cancer development has
been well documented. The bulk of the literature
describe a role of autocrine Wnt signaling resulting
from mutations in the b-catenin degrading complex
(such as APC or GSK3b) or in b-catenin itself that
promote tumor cell proliferation (for review see
Ref. [5]). Both APC and b-catenin mutations lead to
the stabilization of b-catenin and the inappropriate
expression of TCF regulated genes within the tumor
cell, including the transcription factor c-Myc [24], the
cell cycle regulatory protein cyclin-D1 [25], the angio-
genic factor and chemokine IL-8 [26], and the proteases
matrilysin and MMP7 [27,28] which have obvious
implications to tumor development and progression.
In the present study, b-catenin protein was found at
high levels in normal prostate, BPH, PIN, and primary
lesions. b-Catenin protein was also found to simulta-
neously decrease and redistribute from the nucleus to
the cytoplasm in PCa metastases. Although DKK-1 is a
b-catenin target gene, expression of b-catenin likely
does not account for the increase in DKK-1 within
primary lesions as b-catenin levels are similar in both
normal and primary lesion. However, the reduction in
DKK-1 in PCa metastases could be mediated in part by
b-catenin as nuclear expression of b-catenin decreases
in PCa metastases. Although nuclear b-catenin levels
should increase in response to declining DKK-1 levels,
this effect would not necessarily be observed in
PCa epithelial cells where the expression was scored.
b-Catenin levels in the surrounding stroma were not
evaluated. The direct role of b-catenin in both DKK-1
regulation and progression of PCa requires further
study.
We observed that elevated DKK-1 protein levels in
PCa metastases were associated with shorter patient
survival. On the surface this observations seems
inconsistent with the role of canonical Wnt signaling
in promoting tumorigenesis. Our retrospective study
could not determine whether the increased DKK-1
protein resulted from or contributed to primary tumor
development. However, we can speculate that high
DKK-1 expression may reflect a feedback mechanism
whose purpose is to stem unchecked intra-cellular Wnt
signaling. We can further speculate that persistent high
levels of DKK-1 expression in PCa soft tissue meta-
stases may suggest a functional role of DKK-1 in the
formation of these lesions. These data are supported by
published reports that show an elevated expression
of Wnt inhibitors sFRP1, sFRP2, and DKK-1 in human
tumors and that their expression promotes tumor
growth in animal models [29–32]. Conversely, low
levels of DKK-1 in soft tissue metastases of the liver,
lung, lymph node and adrenal may suggest that
canonical Wnt signaling contributes more heavily to
the development of lesions at these sites. The effect of
low levels of DKK-1 expression within bone metastases
could also contribute to the formation of osteoblastic
lesions through Wnts [4,33]. Initial high DKK-1 protein
levels within bone lesions could promote tumor
establishment by inducing bone resorption through
DKK-1’s ability to block Wnt-mediated increase in
osteoprotegerin which would suppress osteoclasto-
genesis [34]. Once the tumor has established within
the bone, subsequent reductions in DKK-1 levels,
as observed in the autopsy array, could permit Wnt-
mediated bone formation and the characteristic osteo-
blastic lesion. In this way, modulation of DKK-1
expression could explain the presence of both osteolytic
and osteoblastic disease in PCa osseous lesions.
Although the association between DKK-1 protein and
tumor stage does not provide a mechanism for an
osteoblastic switch, the analyses presented here are
essential for the design of appropriate mechanism-
based studies.
In conclusion, we provide evidence that DKK-1
protein increases during PCa development but
decreases as the tumor progresses to bone metastases.
We further observe that elevated DKK-1 protein levels
in PCa metastases is associated with shorter patient
survival. These data suggest that DKK-1 expression in
The Prostate
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PCa is an early event necessary to support osteolysis
and early tumor establishment. However as the tumor
progresses, DKK-1 is lost allowing Wnt mediated
osteogenic effect to predominate. The data further
support DKK-1 as a potential prognostic marker and
therapeutic target for PCa.
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